House Bill 2075, also known as the "Helping Open Pathways to Effective (HOPE) Treatment Act," aims to facilitate clinical trials for ibogaine, a psychoactive compound with potential therapeutic benefits for various mental health and neurological conditions. The bill establishes a new chapter in the Tennessee Code Annotated, specifically under Title 33, which outlines the creation of cohorts that include drug developers, research institutions, and hospitals to conduct drug development clinical trials for ibogaine. The cohorts will be responsible for submitting proposals for funding, conducting trials, and ensuring compliance with federal regulations, including seeking approval from the U.S. Food and Drug Administration (FDA).

The legislation also includes provisions for the establishment of a Tennessee mental health innovation fund, which will be funded by revenue generated from intellectual property rights related to the clinical trials. This fund is intended to support behavioral health providers in training and supporting staff for patients undergoing ibogaine therapy. Additionally, the bill mandates that a licensed physician supervise the administration of ibogaine treatments to ensure patient safety. The act will take effect on July 1, 2026, and will only apply if ibogaine receives FDA approval for medical use.